EXAS vs TERN · rev $2.76B vs $6.12B cap
EXACT Sciences Corporation (EXAS) versus Terns Pharmaceuticals Inc (TERN) — a side-by-side from cached financials, not a winner call.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
Terns Pharmaceuticals Inc (TERN) is a biotechnology company listed on NASDAQ.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
Latest reported TERN revenue for 2022-12-31 was $0. Net income was -$60.3M. TERN currently screens at market cap $6.12B.
EXAS currently screens at market cap $20.03B. TERN currently screens at market cap $6.12B.
Not investment advice. Open the EXAS and TERN stock pages for the full models.
Not investment advice.